Loading…

Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity

Toxoplasma gondii is an important pathogen that causes serious public health problems. Currently, therapeutic drugs for toxoplasmosis cause serious side effects, and more effective and novel substances with relatively low toxicity are urgently needed. Ursolic acid (UA) has many properties that can b...

Full description

Saved in:
Bibliographic Details
Published in:Experimental parasitology 2020-09, Vol.216, p.107935, Article 107935
Main Authors: Zhang, Lin-Hao, Jin, Li-Li, Liu, Fang, Jin, Chunmei, Jin, Chun-Mei, Wei, Zhi-Yu
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3
cites cdi_FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3
container_end_page
container_issue
container_start_page 107935
container_title Experimental parasitology
container_volume 216
creator Zhang, Lin-Hao
Jin, Li-Li
Liu, Fang
Jin, Chunmei
Jin, Chun-Mei
Wei, Zhi-Yu
description Toxoplasma gondii is an important pathogen that causes serious public health problems. Currently, therapeutic drugs for toxoplasmosis cause serious side effects, and more effective and novel substances with relatively low toxicity are urgently needed. Ursolic acid (UA) has many properties that can be beneficial to healthcare. In this study, we synthesized eight series of UA derivatives bearing a tetrazole moiety and evaluated their anti-T. gondii activity in vitro using spiramycin as a positive control. Most of the synthesized derivatives exhibited better anti-T. gondii activity in vitro than UA, among which compound 12a exhibited the most potent anti-T. gondii activity. Furthermore, the results of biochemical parameter determination indicated that 12a effectively restored the normal body weight of mice infected with T. gondii, reduced hepatotoxicity, and exerted significant anti-oxidative effects compared with the findings for spiramycin. Additionally, our molecular docking study indicated that the synthesized compounds could act as potential inhibitors of T. gondii calcium-dependent protein kinase 1 (TgCDPK1), with 12a possessing strong affinity for TgCDPK1 via binding to the key amino acids GLU129 and TYR131. [Display omitted] •The synthesized ursolic acid derivatives bearing tetrazole moieties were evaluated for their anti-T. gondii activities.•Compound 12a is a promising hit for the development of new anti-T. gondii agents.•The investigation of the mechanism in vivo and binding mode of action of 12a to TgCDPK1 was performed.
doi_str_mv 10.1016/j.exppara.2020.107935
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1016_j_exppara_2020_107935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014489419305946</els_id><sourcerecordid>32569599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwCaD8QIrtOA-vEKrKQ6rEpl1bfozBVRpHdhravydVCltWV5p778zoIHRP8JxgUjxu53BoWxnknGJ6mpU8yy_QlGCOU8oYv0RTjAlLWcXZBN3EuMUYV4SyazTJaF7wnPMp2ix7We9l53yTeJvsQ_S104nUziQGgusHq4eYfLvuK2l9B03nZJ3IQdK1P_i2lnEnk0_fGOeG2pB23fEWXVlZR7g76wxtXpbrxVu6-nh9XzyvUp0VeZdmwBTHUFmrckpxjpVWVitNy0xDxQ2rgNhyMEuLoSwzJQuaU8yULYwySmYzlI97dfAxBrCiDW4nw1EQLE6YxFacMYkTJjFiGnoPY6_dqx2Yv9YvlyHwNAZg-L53EETUDhoNxgXQnTDe_XPiBxiRfrM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Zhang, Lin-Hao ; Jin, Li-Li ; Liu, Fang ; Jin, Chunmei ; Jin, Chun-Mei ; Wei, Zhi-Yu</creator><creatorcontrib>Zhang, Lin-Hao ; Jin, Li-Li ; Liu, Fang ; Jin, Chunmei ; Jin, Chun-Mei ; Wei, Zhi-Yu</creatorcontrib><description>Toxoplasma gondii is an important pathogen that causes serious public health problems. Currently, therapeutic drugs for toxoplasmosis cause serious side effects, and more effective and novel substances with relatively low toxicity are urgently needed. Ursolic acid (UA) has many properties that can be beneficial to healthcare. In this study, we synthesized eight series of UA derivatives bearing a tetrazole moiety and evaluated their anti-T. gondii activity in vitro using spiramycin as a positive control. Most of the synthesized derivatives exhibited better anti-T. gondii activity in vitro than UA, among which compound 12a exhibited the most potent anti-T. gondii activity. Furthermore, the results of biochemical parameter determination indicated that 12a effectively restored the normal body weight of mice infected with T. gondii, reduced hepatotoxicity, and exerted significant anti-oxidative effects compared with the findings for spiramycin. Additionally, our molecular docking study indicated that the synthesized compounds could act as potential inhibitors of T. gondii calcium-dependent protein kinase 1 (TgCDPK1), with 12a possessing strong affinity for TgCDPK1 via binding to the key amino acids GLU129 and TYR131. [Display omitted] •The synthesized ursolic acid derivatives bearing tetrazole moieties were evaluated for their anti-T. gondii activities.•Compound 12a is a promising hit for the development of new anti-T. gondii agents.•The investigation of the mechanism in vivo and binding mode of action of 12a to TgCDPK1 was performed.</description><identifier>ISSN: 0014-4894</identifier><identifier>EISSN: 1090-2449</identifier><identifier>DOI: 10.1016/j.exppara.2020.107935</identifier><identifier>PMID: 32569599</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alanine Transaminase - blood ; Animals ; Anti-Infective Agents - chemistry ; Anti-Infective Agents - pharmacology ; Anti-Infective Agents - therapeutic use ; Anti-T. gondii ; Aspartate Aminotransferases - blood ; Coccidiostats - chemistry ; Coccidiostats - pharmacology ; Disease Models, Animal ; Docking ; Female ; Glutathione - metabolism ; in vitro ; in vivo ; Liver - drug effects ; Liver - enzymology ; Liver - pathology ; Malondialdehyde - metabolism ; Mice ; Molecular Docking Simulation ; Organ Size - drug effects ; Protein Kinase Inhibitors - pharmacology ; Protein Kinases ; Random Allocation ; Spiramycin - pharmacology ; Spleen - drug effects ; Spleen - pathology ; TgCDPK1 inhibitors ; Toxoplasma - drug effects ; Toxoplasmosis - drug therapy ; Toxoplasmosis, Animal - drug therapy ; Triterpenes - chemistry ; Triterpenes - pharmacology ; Triterpenes - therapeutic use ; Ursolic Acid</subject><ispartof>Experimental parasitology, 2020-09, Vol.216, p.107935, Article 107935</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3</citedby><cites>FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32569599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Lin-Hao</creatorcontrib><creatorcontrib>Jin, Li-Li</creatorcontrib><creatorcontrib>Liu, Fang</creatorcontrib><creatorcontrib>Jin, Chunmei</creatorcontrib><creatorcontrib>Jin, Chun-Mei</creatorcontrib><creatorcontrib>Wei, Zhi-Yu</creatorcontrib><title>Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity</title><title>Experimental parasitology</title><addtitle>Exp Parasitol</addtitle><description>Toxoplasma gondii is an important pathogen that causes serious public health problems. Currently, therapeutic drugs for toxoplasmosis cause serious side effects, and more effective and novel substances with relatively low toxicity are urgently needed. Ursolic acid (UA) has many properties that can be beneficial to healthcare. In this study, we synthesized eight series of UA derivatives bearing a tetrazole moiety and evaluated their anti-T. gondii activity in vitro using spiramycin as a positive control. Most of the synthesized derivatives exhibited better anti-T. gondii activity in vitro than UA, among which compound 12a exhibited the most potent anti-T. gondii activity. Furthermore, the results of biochemical parameter determination indicated that 12a effectively restored the normal body weight of mice infected with T. gondii, reduced hepatotoxicity, and exerted significant anti-oxidative effects compared with the findings for spiramycin. Additionally, our molecular docking study indicated that the synthesized compounds could act as potential inhibitors of T. gondii calcium-dependent protein kinase 1 (TgCDPK1), with 12a possessing strong affinity for TgCDPK1 via binding to the key amino acids GLU129 and TYR131. [Display omitted] •The synthesized ursolic acid derivatives bearing tetrazole moieties were evaluated for their anti-T. gondii activities.•Compound 12a is a promising hit for the development of new anti-T. gondii agents.•The investigation of the mechanism in vivo and binding mode of action of 12a to TgCDPK1 was performed.</description><subject>Alanine Transaminase - blood</subject><subject>Animals</subject><subject>Anti-Infective Agents - chemistry</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Anti-T. gondii</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Coccidiostats - chemistry</subject><subject>Coccidiostats - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Docking</subject><subject>Female</subject><subject>Glutathione - metabolism</subject><subject>in vitro</subject><subject>in vivo</subject><subject>Liver - drug effects</subject><subject>Liver - enzymology</subject><subject>Liver - pathology</subject><subject>Malondialdehyde - metabolism</subject><subject>Mice</subject><subject>Molecular Docking Simulation</subject><subject>Organ Size - drug effects</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinases</subject><subject>Random Allocation</subject><subject>Spiramycin - pharmacology</subject><subject>Spleen - drug effects</subject><subject>Spleen - pathology</subject><subject>TgCDPK1 inhibitors</subject><subject>Toxoplasma - drug effects</subject><subject>Toxoplasmosis - drug therapy</subject><subject>Toxoplasmosis, Animal - drug therapy</subject><subject>Triterpenes - chemistry</subject><subject>Triterpenes - pharmacology</subject><subject>Triterpenes - therapeutic use</subject><subject>Ursolic Acid</subject><issn>0014-4894</issn><issn>1090-2449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EoqXwCaD8QIrtOA-vEKrKQ6rEpl1bfozBVRpHdhravydVCltWV5p778zoIHRP8JxgUjxu53BoWxnknGJ6mpU8yy_QlGCOU8oYv0RTjAlLWcXZBN3EuMUYV4SyazTJaF7wnPMp2ix7We9l53yTeJvsQ_S104nUziQGgusHq4eYfLvuK2l9B03nZJ3IQdK1P_i2lnEnk0_fGOeG2pB23fEWXVlZR7g76wxtXpbrxVu6-nh9XzyvUp0VeZdmwBTHUFmrckpxjpVWVitNy0xDxQ2rgNhyMEuLoSwzJQuaU8yULYwySmYzlI97dfAxBrCiDW4nw1EQLE6YxFacMYkTJjFiGnoPY6_dqx2Yv9YvlyHwNAZg-L53EETUDhoNxgXQnTDe_XPiBxiRfrM</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Zhang, Lin-Hao</creator><creator>Jin, Li-Li</creator><creator>Liu, Fang</creator><creator>Jin, Chunmei</creator><creator>Jin, Chun-Mei</creator><creator>Wei, Zhi-Yu</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202009</creationdate><title>Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity</title><author>Zhang, Lin-Hao ; Jin, Li-Li ; Liu, Fang ; Jin, Chunmei ; Jin, Chun-Mei ; Wei, Zhi-Yu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alanine Transaminase - blood</topic><topic>Animals</topic><topic>Anti-Infective Agents - chemistry</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Anti-T. gondii</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Coccidiostats - chemistry</topic><topic>Coccidiostats - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Docking</topic><topic>Female</topic><topic>Glutathione - metabolism</topic><topic>in vitro</topic><topic>in vivo</topic><topic>Liver - drug effects</topic><topic>Liver - enzymology</topic><topic>Liver - pathology</topic><topic>Malondialdehyde - metabolism</topic><topic>Mice</topic><topic>Molecular Docking Simulation</topic><topic>Organ Size - drug effects</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinases</topic><topic>Random Allocation</topic><topic>Spiramycin - pharmacology</topic><topic>Spleen - drug effects</topic><topic>Spleen - pathology</topic><topic>TgCDPK1 inhibitors</topic><topic>Toxoplasma - drug effects</topic><topic>Toxoplasmosis - drug therapy</topic><topic>Toxoplasmosis, Animal - drug therapy</topic><topic>Triterpenes - chemistry</topic><topic>Triterpenes - pharmacology</topic><topic>Triterpenes - therapeutic use</topic><topic>Ursolic Acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Lin-Hao</creatorcontrib><creatorcontrib>Jin, Li-Li</creatorcontrib><creatorcontrib>Liu, Fang</creatorcontrib><creatorcontrib>Jin, Chunmei</creatorcontrib><creatorcontrib>Jin, Chun-Mei</creatorcontrib><creatorcontrib>Wei, Zhi-Yu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Experimental parasitology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Lin-Hao</au><au>Jin, Li-Li</au><au>Liu, Fang</au><au>Jin, Chunmei</au><au>Jin, Chun-Mei</au><au>Wei, Zhi-Yu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity</atitle><jtitle>Experimental parasitology</jtitle><addtitle>Exp Parasitol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>216</volume><spage>107935</spage><pages>107935-</pages><artnum>107935</artnum><issn>0014-4894</issn><eissn>1090-2449</eissn><abstract>Toxoplasma gondii is an important pathogen that causes serious public health problems. Currently, therapeutic drugs for toxoplasmosis cause serious side effects, and more effective and novel substances with relatively low toxicity are urgently needed. Ursolic acid (UA) has many properties that can be beneficial to healthcare. In this study, we synthesized eight series of UA derivatives bearing a tetrazole moiety and evaluated their anti-T. gondii activity in vitro using spiramycin as a positive control. Most of the synthesized derivatives exhibited better anti-T. gondii activity in vitro than UA, among which compound 12a exhibited the most potent anti-T. gondii activity. Furthermore, the results of biochemical parameter determination indicated that 12a effectively restored the normal body weight of mice infected with T. gondii, reduced hepatotoxicity, and exerted significant anti-oxidative effects compared with the findings for spiramycin. Additionally, our molecular docking study indicated that the synthesized compounds could act as potential inhibitors of T. gondii calcium-dependent protein kinase 1 (TgCDPK1), with 12a possessing strong affinity for TgCDPK1 via binding to the key amino acids GLU129 and TYR131. [Display omitted] •The synthesized ursolic acid derivatives bearing tetrazole moieties were evaluated for their anti-T. gondii activities.•Compound 12a is a promising hit for the development of new anti-T. gondii agents.•The investigation of the mechanism in vivo and binding mode of action of 12a to TgCDPK1 was performed.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32569599</pmid><doi>10.1016/j.exppara.2020.107935</doi></addata></record>
fulltext fulltext
identifier ISSN: 0014-4894
ispartof Experimental parasitology, 2020-09, Vol.216, p.107935, Article 107935
issn 0014-4894
1090-2449
language eng
recordid cdi_crossref_primary_10_1016_j_exppara_2020_107935
source ScienceDirect Freedom Collection 2022-2024
subjects Alanine Transaminase - blood
Animals
Anti-Infective Agents - chemistry
Anti-Infective Agents - pharmacology
Anti-Infective Agents - therapeutic use
Anti-T. gondii
Aspartate Aminotransferases - blood
Coccidiostats - chemistry
Coccidiostats - pharmacology
Disease Models, Animal
Docking
Female
Glutathione - metabolism
in vitro
in vivo
Liver - drug effects
Liver - enzymology
Liver - pathology
Malondialdehyde - metabolism
Mice
Molecular Docking Simulation
Organ Size - drug effects
Protein Kinase Inhibitors - pharmacology
Protein Kinases
Random Allocation
Spiramycin - pharmacology
Spleen - drug effects
Spleen - pathology
TgCDPK1 inhibitors
Toxoplasma - drug effects
Toxoplasmosis - drug therapy
Toxoplasmosis, Animal - drug therapy
Triterpenes - chemistry
Triterpenes - pharmacology
Triterpenes - therapeutic use
Ursolic Acid
title Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20ursolic%20acid%20derivatives%20with%20potential%20anti-Toxoplasma%20gondii%20activity&rft.jtitle=Experimental%20parasitology&rft.au=Zhang,%20Lin-Hao&rft.date=2020-09&rft.volume=216&rft.spage=107935&rft.pages=107935-&rft.artnum=107935&rft.issn=0014-4894&rft.eissn=1090-2449&rft_id=info:doi/10.1016/j.exppara.2020.107935&rft_dat=%3Cpubmed_cross%3E32569599%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c365t-3e4b90e8ffb522050bcbfcbc273ce89d48e1f7fb57f0e773ba625204bf6dbdba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32569599&rfr_iscdi=true